Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

NCT06000397 | Recruiting

• 1 other identifier: 20220678-01H
• Study Type: interventional
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are:

• Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users?
• What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users? Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Conditions

Pneumococcal Vaccines; Immunization Coverage

Keywords

Vaccine coverage; Vaccine uptake

Outcome Measures

Primary Outcomes (1)

• Receipt of 12-month pneumococcal vaccine

  Receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

  12 months of age

Secondary Outcomes (1)

• Timeliness of 12-month pneumococcal vaccine

  12-13 months of age will be considered as timely, after 13 months considered late

Study Arms (2)

Enhanced reminders

EXPERIMENTAL

Other: Enhanced reminders

Standard notifications

ACTIVE COMPARATOR

Other: Standard CANImmunize notifications

Interventions

Enhanced reminders OTHER

The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically: * Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine, * Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and * Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit

Enhanced reminders

Standard CANImmunize notifications OTHER

Push notifications at two time points: * two weeks prior to the immunization due date * one week after the immunization due date

Standard notifications

Eligibility Criteria

• Age: 10 Months - 11 Months
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• To be included in the study, CANImmunize account holders must have:
• Enabled the reception to receive emails from CANImmunize, and
• Record(s) for an infant aged between 10- and 11-months, who have already received the earlier doses of the pneumococcal vaccine in accordance with their provincial/territorial routine immunization schedule.

You may not qualify if:

• The account holder (parent, or guardian of the child) has an inactive or undelivered email address, or
• No record(s) for an infant aged 10- and 11-months, or
• The record for the 10- or 11-month-old indicates that he/she has not received the prior pneumococcal vaccine doses.

Sponsors & Collaborators

• Ottawa Hospital Research Institute: lead

Study Sites (1)

CANImmunize

Ottawa, Canada

RECRUITING

Central Study Contacts

Kathryn MacDonald

CONTACT

613-293-1193; kathryn@canimmunize.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 14, 2023
• First Posted: August 21, 2023
• Study Start: November 7, 2023
• Primary Completion: June 1, 2024
• Study Completion: June 1, 2024
• Last Updated: April 9, 2024

Record last verified: 2024-04

Locations

CA (1)